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 ABSTRACT 
 The objective of this study was to evaluate the ef-
ficacy of intramammary treatment with ceftiofur 
hydrochloride of nonsevere, clinical coliform mastitis. 
One hundred four cases on 5 farms met the enrollment 
criteria for the study. Escherichia coli was the most 
common coliform species identified in milk samples 
from cows with mild to moderate clinical mastitis, 
followed by Klebsiella spp. and Enterobacter spp. At 
enrollment, a milk sample from the affected quarter 
was taken and used for on-farm culture or submitted 
to the laboratory. For cows in the treatment group, 
treatment was initiated with ceftiofur hydrochloride via 
intramammary infusion at 24-h intervals for 5 d accord-
ing to label standards. Cows in the control group did 
not receive treatment. Culture results were available on 
the day after enrollment and only cows with coliform 
mastitis continued in the treatment and untreated con-
trol groups. Bacteriological cure was defined based on 
2 posttreatment milk samples. Molecular typing was 
used for final definition of bacteriological cure. Treat-
ment of nonsevere clinical gram-negative mastitis with 
ceftiofur hydrochloride resulted in a significant increase 
in bacteriological cure compared with nontreated con-
trols in animals infected with E. coli or Klebsiella spp. 
Treated animals clinically improved significantly more 
compared with control cows. No significant differences 
were observed between treated and control animals in 
milk production or linear score before or after clinical 
mastitis. Treated animals left the study less frequently 
compared with control animals. 
 Key words:   gram-negative mastitis ,  ceftiofur hydro-
chloride ,  Escherichia coli ,  Klebsiella 
 INTRODUCTION 
 Mastitis is widespread in dairy herds. It is the most 
costly disease to animal agriculture in the United States 
and throughout much of the world. It affects animal wel-
fare and results in decreased milk yield, increased cost 
of milk production, and reduced milk quality (Barkema 
et al., 1998; Gröhn et al., 2004). In dairy cows, mastitis 
is usually caused by bacteria or other microorganisms 
that enter the mammary gland. Gram-negative bacte-
ria, mostly coliforms (Escherichia coli, Klebsiella spp., 
and Enterobacter spp.), may cause a high proportion of 
all clinical mastitis (CM) cases (Barkema et al., 1998; 
Olde Riekerink et al., 2008; Breen et al., 2009; Nam et 
al., 2009). In published field studies, 15 to 25% of cows 
in well-managed herds are diagnosed annually with 
CM caused by coliforms (Erskine et al., 1988; Hogan 
and Smith, 2003). The most common coliform species 
reported to cause CM are E. coli and Klebsiella spp. 
(Todhunter et al., 1991; Erskine et al., 2002a,b; Munoz 
et al., 2007). Klebsiella spp. appear to be particularly 
important in North American herds. 
 Results from experimental studies and field studies 
on mastitis caused by E. coli or other coliforms have 
been equivocal. Experimental challenge studies with E. 
coli conducted by Pyörälä et al. (1994) with 6 cows per 
treatment group showed no positive effect of treatment 
with local colistin sulfate or parenteral trimethroprim 
sulfadiazine. Using an experimental E. coli challenge 
and 2 cows per treatment group, Rantala et al. (2002) 
observed a positive effect of parenteral enrofloxacin 
administration on milk yield but not on clinical signs 
or survival. In an experimental challenge study with 6 
cows per treatment group, Hoeben et al. (2000) also 
demonstrated a beneficial effect of enrofloxacin on milk 
yield but not on general clinical signs or milk score 
after experimental challenge with E. coli. Systemically 
administered danofloxacin had a positive effect on milk 
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yield and on bacteriological results and systemic and lo-
cal clinical signs in a negative controlled E. coli experi-
mental challenge trial (Poutrel et al., 2008). In contrast 
to experimental studies, a field study of natural E. coli 
mastitis did not show a beneficial effect of enrofloxa-
cin (Suojala et al., 2010). Conflicting results have also 
been obtained for cephalosporins. A positive controlled 
experimental challenge trial with a total of 47 cows 
showed that parenteral administration of cefquinome 
resulted in more clinical and bacterial cure than use of 
intramammary amoxicillin and cloxacillin (Shpigel et 
al., 1997). A field study with 29 treated cases and 27 
untreated controls of naturally occurring severe clini-
cal mastitis caused by coliform organisms showed that 
intramuscular treatment with ceftiofur reduced the 
risk of death or culling (Erskine et al., 2002a). In a 
field study of 33 cows with mild clinical mastitis cases 
that were predominantly caused by E. coli, however, 
intramuscular ceftiofur treatment in combination with 
intramammary cephapirin treatment did not have 
beneficial effects (Wenz et al., 2005) compared with 
intramammary treatment alone. The observation that 
systemic ceftiofur treatment does not improve the cure 
of intramammary infection is not unexpected because 
systemic ceftiofur treatment does not result in appre-
ciable titers in milk in cows without systemic clinical 
signs (Erskine et al. 1995). When in the Wenz et al. 
(2005) study, the intramammary cephapirin treatment 
alone was compared with an intramammary treatment 
with pirlimycin (an antibiotic not efficient against co-
liform bacteria), a difference in bacteriological cure of 
coliforms of 18 percentage points was observed (50% 
vs. 32%, respectively). Because of the small number of 
animals in the study, however, this difference was not 
statistically significant (P = 0.2).
Treatment of E. coli CM with intramammary ceftio-
fur hydrochloride received FDA approval in the United 
States based on a field study showing 86% bacteriologi-
cal cure in treated cows versus 46% bacteriological cure 
in control cows (FDA, 2005). However, the numbers of 
cows treated in each of the treatment arms of the study 
were relatively small, with 14 and 13 cows in the treat-
ment and control groups, respectively. No efficacy data 
of ceftiofur against Klebsiella spp. mastitis are currently 
available even though Klebsiella mastitis is emerging as 
an important cause of clinical mastitis on dairy farms, 
particularly in the United States (Munoz et al., 2007). 
Generally, both E. coli and Klebsiella spp. isolated from 
bovine mastitis cases have been found to be susceptible 
in vitro to third-generation cephalosporins (Srinivasan 
et al., 2007; Bengtsson et al., 2009; Nam et al., 2009).
The objective of this study was to evaluate the ef-
ficacy of intramammary treatment of nonsevere, 
clinical coliform mastitis with ceftiofur hydrochloride. 
Particularly, the bacteriological cure rates and clinical 
symptoms of cows treated with ceftiofur hydrochloride 
were compared with those of control cows that were not 
treated with antimicrobials (negative controls).
MATERIALS AND METHODS
Farm Inclusion Criteria
Inclusion criteria for farms included (1) having at 
least 500 cows milking on a given day, (2) availability of 
reliable health records, and (3) access to culture results 
from milk samples of CM cases within 1 d of sample 
collection. Preferably, farms that made use of DHIA 
services, including monthly SCC, were included. Health 
records included calving, treatment, vaccination, fertil-
ity, and culling data. Herds were allowed to vaccinate 
against coliform mastitis (J5) as long as all cows re-
ceived the same vaccination program. Access to culture 
results within 1 d of sample collection was achieved 
through use of on-farm culture systems or daily sample 
pick-up through the Quality Milk Production Services 
(QMPS) program. Farms included in the study (A to 
E) are described in Table 1.
Study Design and Quality Assurance
Sample size was calculated using the following as-
sumptions: one-sided significance level, α, at 0.05, 
power, 1 − β, at 0.8 assumed cure rate in the controls 
of 0.5 and in the treated group of 0.7 or higher. The 
estimated study size was 50 cases per treatment group 
or approximately 100 cows to be enrolled in the trial. 
A one-sided significance level was used because realisti-
cally no negative effect of treatment was expected. The 
study was conducted as a randomized block design with 
cows within herds randomly assigned to the treatment 
or control group. Randomization was based on ear tag 
number. For each herd, cows with odd ear tag num-
bers were assigned to the treatment group and cows 
with even ear tag numbers were assigned to the con-
trol group. Treatment instructions were in numbered 
binders. Intramammary treatments were administered 
by trained farm personnel. Clinical assessments were 
performed by trained farm personnel before the first 
treatment, once a day thereafter until the completion 
of treatment, and by QMPS personnel when follow-up 
samples were collected. All clinical recordings, treat-
ments, and follow-up measurements were recorded on 
case record forms and signed off by the person mak-
ing the observations. All binders were accounted for 
on the dairy. Data were entered electronically by one 
of the authors (HLS) and double-checked for accuracy. 
Copies of the computerized herd record-keeping sys-
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tem (DairyComp305, Valley Ag Software, Tulare, CA) 
were collected regularly. Milk production and SCC 
were taken from DHIA test-days and extracted from 
the DairyComp305 records. If available, data from 3 
test-days were obtained immediately before and after 
the case of clinical mastitis. After completion of the 
treatment, and at equivalent time points for untreated 
control cows, 2 follow-up milk samples were collected 
by QMPS personnel at 7 ± 2 d and 14 ± 2 d after 
the last treatment. Follow-up samples were taken at 7 
and 14 d after the last treatment to accommodate the 
relatively short duration of E. coli IMI (Pyörälä et al., 
1994; Hoeben et al., 2000), thereby preventing the risk 
of new infections to distort the observed cure risks. All 
mastitis samples and follow-up samples were submit-
ted to a QMPS laboratory, including samples that had 
been used for on-farm culture.
Cow Inclusion Criteria and Treatment
Cows were eligible for inclusion in the study if they 
had not been treated with antibiotics in the last 14 
d and did not show severe teat lesions due to recent 
trauma. Cows were eligible for inclusion from the day of 
calving (inclusive) until 25 d before dry-off. A cow was 
only eligible to be included once in the study. Cows were 
enrolled when they presented with signs of nonsevere 
(mild or moderate) CM in one quarter. At enrollment, 
a milk sample from the affected quarter was taken us-
ing standard aseptic technique (NMC, 1999), used for 
on-farm culture, and submitted to QMPS. Cows only 
continued in the study if the on-farm or QMPS culture 
result at 24 h after inclusion showed the presence of co-
liform organisms. Eventually, cows were only included 
in this analysis when the enrollment sample was con-
firmed to be coliform positive at the QMPS laboratory. 
For cows in the treatment group, treatment with ceftio-
fur hydrochloride (125 mg in 10 mL, Spectramast LC, 
Pfizer Animal Health, New York, NY) was initiated 
via intramammary infusion at 24-h intervals for 5 d 
according to label standards. Cows in the control group 
did not receive treatment on the day of enrollment. 
On the day after enrollment, culture results were avail-
able and only cows with coliform mastitis continued in 
the treatment and untreated control groups. All other 
animals (e.g., animals with gram-positive mastitis or 
culture negative milk samples) were excluded from the 
study and could be treated at the discretion of the herd 
manager or veterinarian. The study was approved by 
the Cornell University Institutional Animal Care and 
Use Committee.
Clinical Scoring System
The clinical scoring system described and evaluated 
by Wenz et al. (2001, 2006) was used to classify CM se-
verity. A score of mild was assigned when the milk was 
abnormal (flakes, watery, clots, or bloody) and no other 
local or systemic signs of inflammatory disease were 
observed. A score of moderate was assigned if the milk 
was abnormal, swelling or pain of the affected mamma-
ry gland was noted, and only one of the systemic signs 
of inflammatory disease defined below was observed. A 
score of severe was assigned when the milk was grossly 
abnormal, swelling or pain of the affected gland was 
noted, and at least 2 of the following systemic disease 
signs were seen: rectal temperature ≥39.5°C, moderate 
to marked enophthalmos (>3 mm), or marked depres-
sion defined as inappetence or not able to stand or both 
(Wenz et al., 2001, 2006). For analysis of the data, each 
milk, mammary, or systemic sign described above was 
coded as present (1) or absent (0), resulting in a milk 
Table 1. Basic description upon entering the study of 104 enrolled coliform mastitis cases in 5 farms (A to E, all in New York State)1 
Item A B C D E Total
Herd size (milking cows) 546 789 548 752 699  
Bulk milk SCC (× 1,000 cells/mL) 195 265 256 199 358  
Culture method On-farm On-farm On-farm On-farm QMPS2  
Daily milk yield [kg/d (SD)] 41.4 (21.2) 40.5 (23.7) 36.4 (19.8) 35.5 (21.9) 37.3 (20.1)  
Total mastitis cases (no.) 131 143 30 62 86 452
Total cases enrolled (no.) 35 23 10 4 24 96
Ceftiofur (no.) 18 18 5 2 13 56
Control (no.) 17 13 5 2 11 48
Escherichia coli 3 19 3 2 22 49
Klebsiella spp. 18 12 7 2 1 40
Enterobacter cloacae 14 0 0 0 1 15
Ceftiofur bacteriological cure [no. (%)] 12 (67) 14 (78) 2 (40) 1 (50) 12 (92) 41 (73)
Control bacteriological cure [no. (%)] 7 (41) 2 (15) 1 (20) 0 (0) 8 (73) 18 (38)
1Culture results are from the pretreatment milk sample.
2QMPS = Quality Milk Production Services.
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score from 0 to 4, a mammary score from 0 to 2, and a 
systemic score from 0 to 3. The total clinical score then 
ranged between 0 and 9.
Cows were considered clinically cured if all posttreat-
ment scores were completely normal (score = 0). Any 
abnormality at either of the 2 follow-up evaluations 
was considered a clinical noncure. Because complete 
absence of any clinical signs within 14 d after the end 
of treatment may be difficult to achieve from any treat-
ment, we also evaluated clinical improvement of the 
included cows. A cow was defined as clinically improved 
if the clinical score at the 14-d posttreatment evalua-
tion was 50% or less of the score obtained at the initial 
diagnosis of clinical mastitis. That is, the animal had 
improved her clinical score by at least 50%.
Bacteriological Identification  
and Definition of Infection
A quarter was considered infected with a coliform or-
ganism and included in the analysis if the milk sample 
taken immediately before enrollment was confirmed to 
be coliform positive at the QMPS laboratory. Approxi-
mately 0.01 mL of milk was streaked on trypticase soy 
agar containing 5% sheep blood and 0.1% esculin (PML 
Microbiologicals, Mississauga, ON, Canada), and plates 
were incubated aerobically at 37°C for 48 h. After ob-
servation of colony morphology and hemolytic patterns 
on blood agar, isolates were examined further by means 
of 3% KOH, Gram staining of organisms, catalase and 
oxidase testing, and additional biochemical and meta-
bolic evaluations as needed. Gram-negative organisms 
were identified by colony morphology on MacConkey’s 
agar (National Mastitis Council, 1999). Lactose-posi-
tive, citrate-negative colonies surrounded by bile-salt 
precipitate on MacConkey agar were considered E. coli, 
and yellow or pink mucoid colonies without precipi-
tate and motility negative were considered Klebsiella 
spp. Klebsiella pneumoniae and Klebsiella oxytoca were 
differentiated using indol. For isolates that were phe-
notypically identified as belonging to the genus En-
terobacter, species identity was determined based on 
rpoB sequencing (Munoz et al., 2007). Strain typing 
was used to compare pre- and posttreatment isolates if 
the same bacterial species was observed before and af-
ter treatment of a quarter. Per quarter, between 1 and 
5 isolates were selected depending on the number of 
isolates available before and after treatment. In several 
cows, quarters were also sampled during treatment, and 
isolates obtained from these samples were evaluated us-
ing molecular strain typing. Strain typing was also used 
for comparison across quarters within bacterial species 
within herds. Strain typing was performed by means 
of random amplified polymorphic DNA (RAPD)-PCR 
(Munoz et al., 2007). Reproducibility of RAPD band-
ing patterns was evaluated using an arbitrary selection 
of 18 isolates for which lysates were prepared on 2 or 3 
occasions, 3 wk to 10 mo apart.
Bacteriological cure was defined based on culture re-
sults from 2 posttreatment samples and RAPD typing. 
Both posttreatment samples had to be present and the 
coliform species identified in the pretreatment sample 
had to be absent from both posttreatment samples. 
When the same bacterial species was identified but 
RAPD typing revealed a different strain pretreatment 
and posttreatment, the case was defined as a bacterio-
logical cure followed by a new infection. All statistical 
analyses were performed in SAS software (version 9.2, 
SAS Institute Inc., Cary, NC).
Statistical Analysis
Data were initially analyzed using descriptive statis-
tics, and descriptive statistics in treatment and control 
groups were compared using a t-test. Outliers and 
missing data were further investigated. Cows did not 
necessarily have complete SCC and milk production 
data before or after treatment because some cows had 
mastitis in early lactation and some cows were dried-off 
or culled before 2 or 3 test-days had passed. For these 
reasons, analysis of production and cell count data was 
done on a subgroup of animals. We defined the sub-
group for test-day analysis as cows that had at least 
2 pretreatment milk production and SCC data points 
and 2 posttreatment milk production and SCC data 
points. Milk production and SCC data [after transfor-
mation to linear score (LS) using the formula LS = 
log2 (SCC/100) + 3, where SCC is expressed in units 
of 1,000 cells/mL] were analyzed using a linear mixed 
model. The model used for this analysis was
Milk (or LS) = Lactation + DIM + Herd  
+ Pathogen + TRMastitis + treatment + Re,
where Milk or LS is the test-day milk yield (kg) or 
linear score, lactation is the lactation number catego-
rized in 3 categories (1, 2, and 3+), DIM is days in 
milk in ten 30-d categories, Herd is a set of indicator 
variables indicating herd of origin, Pathogen is a set 
of indicator variables indicating the causal bacterial 
species, TRMastitis is a set of indicator variables indi-
cating −2, −1, 1, or 2 tests relative to the occurrence 
of clinical mastitis, treatment indicates treatment or 
control group, and Re is a complex error term consist-
ing of within-cow correlation of test day measurements 
(REPEATED statement) and a random error term. 
Two-way interactions were tested and included in the 
model where significant.
Journal of Dairy Science Vol. 94 No. 12, 2011
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Clinical cure, clinical improvement, and bacteriologi-
cal cure were analyzed using logistic regression analysis. 
Separate analyses were performed for all cases com-
bined and for each bacterial species or genus (E. coli, 
Klebsiella, Enterobacter) separately. For all regression 
models, the linear predictor was given by
Logit (cure) = Lactation + DIM + Herd  
+ Pathogen + treatment + e,
where cure is clinical cure, clinical improvement, or 
bacteriological cure, and Lactation (in 3 categories: 
1, 2, and 3+), DIM (in ten 30-d categories), Herd, 
Pathogen (E. coli, Klebsiella spp., or Enterobacter), and 
treatment were included as fixed effects, and e was a 
binomial error term.
Time to exit from the study was defined as the time 
between entrance into the study and exit from the study. 
Exit could be due to completion of all data collection 
(normal exit, treated as censoring in the analysis) or 
early exit due to culling, death, or intervention by the 
farmer. Farmer intervention was allowed in the protocol 
when the clinical status of the cow deteriorated. The 
farmer indicated the reason for study exit and was free 
to choose a different or additional treatment for the 
animal. Time to culling or death was defined as the 
time between entrance in the study and either culling 
or death in the lactation where the case of mastitis 
occurred. Time to event analysis was performed using 
Kaplan-Meier survival curves and statistically evalu-
ated using Cox proportional hazard models. The linear 
predictor of the Cox proportional hazards model was
Hazard (exit) = Base × Exp[Lactation + DIM  
+ Herd + Pathogen + treatment (or cure)],
where exit is time to exit, and Lactation, DIM, Herd, 
and Pathogen were as defined above and included as 
fixed effects. The effect of treatment versus control and 
bacteriological cure versus failure was evaluated in 2 
separate analyses.
For all outcome variables, treatment was compared 
with the control group using one-sided significance 
tests with a 5% significance level (P-value). All other 
explanatory variables in the model were evaluated us-
ing a 2-sided significance test with a P-value of 5%.
RESULTS
Cows Enrolled
In total, 104 cases on 5 farms met the enrollment 
criteria for the study. Farm characteristics are shown 
in Table 1 and cow characteristics are shown in Table 
2. Mild to moderate CM due to coliform infections 
was diagnosed in early, mid, and late lactation. Ap-
proximately 40% of cases occurred in the first 100 DIM 
and the remainder occurred later in lactation. Average 
DIM was 136 (SD 97) for treated cows and 140 (SD 
88) for control cows (t-test, P = 0.82). The majority 
of affected animals were multiparous cows, with ap-
proximately 20% of cows in first lactation. Average 
lactation number was 2.5 (SD 1.2) for treated cows 
and 2.7 (SD 1.4) for control cows (t-test, P = 0.54). 
Prior to enrollment, milk production of affected cows, 
as measured at the last test-day before CM, ranged 
from <25 to >65 kg/d. Before mastitis, treated animals 
had an average production of 45.6 (SD 15.6) kg/d and 
control animals produced 44.3 (SD 10.9) kg/d (t-test, P 
= 0.54). Treated animals had a pretreatment LS of 3.3 
(SD 2.1), whereas control animals had a pretreatment 
LS of 3.1 (SD 1.9; t-test, P = 0.70).
Microbiology and Molecular Typing
Escherichia coli was the most common coliform spe-
cies identified in milk samples from cows with mild 
to moderate CM, followed by Klebsiella spp. and En-
terobacter spp. (Table 1). Clear differences were found 
between herds in distribution of bacterial species or 
Table 2. Characteristics of 104 cows with clinical mastitis (CM) cases treated with ceftiofur or untreated (SD 
in parentheses) controls 
Parameter Ceftiofur Control P-value
Cases (no.) 56 48  
 Escherichia coli 29 19  
 Klebsiella spp. 20 18  
 Enterobacter cloacae 7 11  
Cow characteristics    
 Lactation number 2.5 (1.2) 2.7 (1.4) >0.50
 Stage of lactation (d) 135.7 (97.2) 139.6 (87.6) >0.80
 Milk production before CM (kg) 45.6 (15.6) 44.3(10.9) >0.50
 Linear score before CM 3.3 (2.1) 3.1 (1.9) >0.70
 SCC before CM (× 1,000 cells/mL) 310.4 (424.8) 369.1 (892.7)  
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genera. Herd A showed a predominance of Klebsiella 
spp. and Enterobacter spp., whereas herd E had pre-
dominantly E. coli infections. All Klebsiella isolates 
were identified as Klebsiella pneumoniae with the ex-
ception of one Klebsiella oxytoca in farm B. Because 
of the vast dominance of Klebsiella pneumoniae in 
the data, all Klebsiella isolates were analyzed as one 
group, identified as Klebsiella spp. All Enterobacter 
isolates that were subjected to rpoB sequencing were 
identified as E. cloacae (99% species identity based on 
100% coverage of 900-bp fragment). Reproducibility of 
RAPD banding patterns was excellent, unless lysates 
had been prepared 10 mo apart, in which case subtle 
differences in band intensity were observed. To ensure 
that this did not affect comparisons of RAPD patterns 
within quarters, cows, or herds, only sets of lysates 
that were prepared at the same time were used for 
comparisons. The RAPD patterns for Klebsiella spp. 
isolates all showed a band of approximately 200 bp, 
and RAPD patterns for E. cloacae isolates all showed 
a band of approximately 290 bp. The RAPD patterns 
for E. coli showed only bands that were larger than 300 
bp (Figure 1). Isolates for strain typing were available 
from 33 of 35 cows in herd A, 28 of 31 cows in herd 
B, 8 of 10 cows in herd C, 0 of 4 cows in herd D, and 
18 of 24 cows in herd E. Of the 17 cows for which 
strain typing data were not available, 7 were considered 
treatment failures because they were culled and 8 were 
considered treatment successes because they were cul-
ture negative posttreatment. For 25 animals, cure deci-
sions depended on strain typing data. This included 2 
animals for which no strain typing data were available 
and 2 animals for which only pretreatment strain typ-
ing data were available. Of the remaining 21 animals, 
17 were considered noncured because the same strain 
was detected before and after treatment, and 4 animals 
were considered cured because strains differed before 
and after treatment (Figure 1). When multiple isolates 
were available from a quarter before or after treatment, 
respectively, isolates belonged to the same strain for 
44 of 46 episodes. One animal showed 2 strains among 
2 pretreatment isolates and 1 animal showed 2 strains 
among 3 posttreatment isolates. Neither result affected 
cure decisions. Because of strain heterogeneity within 
herds, the number of observations per strain was too 
small for strain-specific assessment of cure, even though 
some strains were identified in multiple animals within 
herds (Table 3).
Bacteriological Cure
Across herds and species, 38% of control cows and 
73% of the treated cows showed a bacteriological cure 
(Table 1). Important differences were observed between 
herds. The difference between treated and control 
animals was largest in herd B with a 63 percentage 
point increase in cure and was smallest in herd E with 
an increase of 19 percentage points (Table 1). To be 
considered a bacteriological cure, both posttreatment 
samples needed to be present. This was the case in 
36 (75%) of the control animals and in 50 (89%) of 
Figure 1. Examples of random amplification of polymorphic DNA 
(RAPD) typing results for 8 cows with Escherichia coli (top panel; 
herd E), Klebsiella pneumoniae (middle panel; herd C), or Enterobacter 
cloacae (bottom panel; herd A). Letters indicate strains (A through 
H) or DNA ladder (L) and should be compared within panels only; 
roman numerals indicate cows; D1, D2, D4, and D5 indicate d 1, 2, 
4, and 5 of treatment, respectively; P1, P2, and P3 indicate d 1, 2, 
and 3 posttreatment, respectively. Strains are persistent within udder 
quarters (no cures) but may be different between cows for E. coli and 
E. cloacae. In the Klebsiella example, cow II would be considered cured 
(different strains pre- and posttreatment) whereas cow VI would be 
considered not cured (same strain pre- and posttreatment).
Journal of Dairy Science Vol. 94 No. 12, 2011
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the treated animals. When no or only one sample was 
available, the animals were classified as a bacterio-
logical failure. Bacteriological cure was highest in E. 
coli-infected cows with 73%. Bacteriological cure was 
61% in E. cloacae-infected cows and 44.7% in Klebsiella 
spp.-infected cows. Figure 2 shows the least squares 
means of bacteriological cure by treatment group and 
pathogen.
Logistic regression results are shown in Table 4. 
Logistic regression analysis was performed across all 
farms and across the 3 pathogens. This logistic regres-
sion analysis showed a significant treatment effect (P 
= 0.0004) with an odds ratio of 9.2 (95% CI: 2.5–33.6). 
When the logistic regression analysis for E. coli was 
performed separately, ceftiofur treatment was statis-
tically significant (P = 0.007), with an odds ratio of 
112 (95% CI: 2.8–397.3). For Klebsiella spp., treatment 
with ceftiofur was also significantly better compared 
with no treatment (P = 0.02) with an odds ratio of 8.5 
(95% CI: 1.1–30.1). For the E. cloacae-infected quar-
ters, treatment was not significantly different from the 
nontreated controls (P = 0.39).
Table 3. Distribution of random amplification of polymorphic DNA (RAPD) types among coliform species 
within herds 
Herd Species
Number
Strain frequency1Isolates Strains
A Enterobacter cloacae 15 3 9, 5, 1
Klebsiella spp. 16 10 6, 2, 1, 1, 1, 1, 1, 1, 1, 1
Escherichia coli 2 2 1, 1
B Klebsiella spp. 10 8 2, 2, 1, 1, 1, 1, 1, 12
E. coli 18 9 5, 3, 3, 2, 1, 1, 1, 1, 1
C Klebsiella spp. 5 4 2, 1, 1, 1
E. coli 3 3 1, 1, 1
D Klebsiella spp. 1 1 1
E. coli 17 10 5, 2, 2, 2, 1, 1, 1, 1, 1, 1
1Number of isolates per RAPD type in descending frequency. For example, of E. cloacae isolates in herd A, 
9 showed the most common RAPD type, 5 showed the second most common RAPD type, and 1 showed the 
third RAPD type.
2One isolate was identified as Klebsiella oxytoca; all other Klebsiella isolates in all farms were identified as 
Klebsiella pneumoniae.
Figure 2. Least squares means by bacterial species of the final logistic regression models of bacteriological cure, clinical cure, and clinical 
improvement. E. coli = Escherichia coli; E. cloacae = Enterobacter cloacae.
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Clinical Cure and Clinical Improvement
Clinical cure was defined as the complete absence 
of any clinical mastitis sign on both posttreatment 
sampling days; presence of any sign was considered a 
clinical failure. Of the cows that were defined as a clini-
cal failure, 18 did not have data for both posttreatment 
days, 16 had watery milk, 15 still showed some evidence 
of clots or flakes, 12 had a swollen quarter, and 2 showed 
systemic signs of illness. Among all cows, 50% showed 
full clinical cure at both posttreatment sampling days. 
Proportion of clinical cure was 46% for control cows 
versus 54% for treated cows. Distribution of clinical 
cure among causal coliform bacteria and by treatment 
group is shown in Figure 2. The proportion of clini-
cal cure was highest in cows infected with E. cloacae 
(72%) and lowest in cows infected with E. coli (42%). 
Logistic regression analysis on clinical cure, corrected 
for farm, lactation number, and DIM, showed an in-
creased odds of cure for treated animals (odds ratio 9.2, 
95% CI: 2.5–33.6; P < 0.01). In the logistic regression 
model, both E. coli- and Klebsiella spp.-infected cows 
were less likely to show clinical cure compared with the 
E. cloacae-infected cows, but this was not statistically 
significant. Clinical improvement (reduction of clinical 
score by at least 50%) was present in 63% of treated 
cows and in 50% of control cows. The logistic regression 
analysis showed a significantly lower clinical improve-
ment in animals infected with E. coli and Klebsiella 
spp. compared with cows infected with E. cloacae (the 
odds ratio were 0.16 and 0.24, respectively; P < 0.05 
for both). Treated cows were significantly more likely 
to show clinical improvement compared with controls 
(odds ratio 2.4; P < 0.05).
Milk Production and SCC
A relatively small number of cows had milk produc-
tion data before and after clinical mastitis. In total, 29 
of the 48 control cows (60%) and 32 of the 56 treated 
cows (57%) had sufficient milk production data avail-
able. Production decreased considerably after a case 
of CM (Figure 3). Both treated and control cows lost 
approximately 5 kg in milk production as measured on 
the next test-day after the clinical case. No significant 
difference in milk production decrease or recovery was 
seen between treated and control cows. When cows that 
showed bacteriological cure were compared with cows 
that did not cure, a significant difference in milk pro-
duction recovery was observed. At the second test-day 
after the case of CM, cured cows had milk production 
that was approximately 4 kg higher than that of non-
cured cows (P < 0.05; Figure 3).
Linear scores before and after treatment are shown 
in Figure 3. Because of many animals with incomplete 
data, only 36 animals (15 controls and 21 treated cows) 
that had at least 2 pre- and 2 posttreatment test-days 
with LS data contributed to this analysis. Linear score 
before clinical mastitis was lower in control cows com-
pared with treated cows (2.6 vs. 3.6). Linear score in 
the first test-day after CM was 4.6 in treated cows 
compared with 3.3 in control cows. In both groups, 
Table 4. Results of logistic regression analysis of bacteriological cure; the final models for all cases, Escherichia coli, and Klebsiella spp. cases 
are shown1  
Parameter
All cases E. coli Klebsiella spp.
Coefficients
Odds  
ratio Coefficients
Odds  
ratio Coefficients
Odds  
ratio
Intercept 1.65 (1.49)  0.41 (1.28)  −12.57 (535.1)  
Herd In model  In model In model  
Lactation       
 1 0.65 (0.80) 1.90 3.1 (1.96) 22.2 −0.79 (1.33) 0.45
 2 −0.77 (0.65) 0.46 −0.87 (1.31) 0.42 0.54 (1.03) 1.72
 3+ Baseline Baseline Baseline  
DIM In model In model In model  
Pathogen       
 E. coli −0.19 (1.04) 0.83 Only E. coli    
 Klebsiella spp. −1.03 (0.87) 0.35   Only Klebsiella spp.  
 E. cloacae Baseline  
Treatment       
 Ceftiofur 2.22 (0.62)* 9.21 4.72 (1.7)* 112.2 2.14 (1.02)* 8.50
 Control Baseline Baseline Baseline  
1Logistic regression coefficient and standard deviation.
*P < 0.05. 
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LS dropped thereafter to 3.9 and 2.8, respectively. No 
significant differences were found in LS either before or 
after treatment. Cows with bacteriological cure showed 
statistically nonsignificant but higher LS in the first 
test-day after CM (4.3 in cured animals vs. 3.4 in non-
cured animals).
Exit from the Study and Exit from the Herd
Twenty-three animals were removed from the study 
early. Of these 23 animals, 13 were in the control group 
(13 of 48, 27%) and 10 were in the treated group (10 of 
56, 18%). Early culling from the herd or death occurred 
in 16 animals, 9 of which were control animals (19%) and 
7 of which were treated animals (12%). Figure 4 shows 
the survival curves for time to exit from the study and 
time to exit from the herd. Survival curves are shown 
for treated versus control cows and for bacteriologically 
cured versus noncured cows. Cox proportional hazard 
models showed a significant difference in time to exit 
from the study between treated and control cows. The 
hazard ratio of exit from the study between treated 
versus control cows was 0.25 (95% CI: 0.09–0.67; P 
< 0.05). Cows that were bacteriologically cured had 
a hazard ratio of exit from the study compared with 
noncured cows of 0.04 (95% CI: 0.01–0.21; P < 0.05). 
The hazard ratio of exit from the herd in treated versus 
control cows was 0.62 (95% CI: 0.19–1.97; P > 0.2). 
In bacteriologically cured versus noncured cows the 
hazard ratio was 0.19 (95% CI: 0.05–0.68; P < 0.05).
DISCUSSION
Across farms, animals in treatment and control 
groups did not differ significantly in parity, lactation 
stage, milk production, or SCC at the time of enroll-
ment. However, after the occurrence of clinical coliform 
mastitis, significant and important differences were 
observed between treated and control groups. Across 
farms and coliform species, 5-d treatment with ceft-
iofur resulted in a significantly higher probability of 
cure compared with no treatment. Across herds and 
Figure 3. Least squares means of the final models for milk production (left) and linear score (right) before and after treatment in treated and 
control cows (top) and in bacteriologically cured and noncured animals (bottom). Sixty-one cows were included in the milk production analysis 
(32 treated, 29 control) and 36 in the linear score analysis (21 treated, 15 control).
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bacteriological species, bacteriological cure was 73% in 
treated animals and 38% in control animals. For quar-
ters infected with E. coli, bacteriological cure was 89% 
in treated animals versus 53% in control animals, and 
for quarters infected with Klebsiella, bacteriological 
cure was 57% in treated animals versus 19% in control 
animals. Quarters infected with E. cloacae showed no 
difference in bacteriological cure between treated and 
control animals, although this finding was based on a 
relatively small sample. Although E. cloacae IMI are 
not generally reported, they have been observed as a 
cause of clinical mastitis (Nam et al., 2009).
This study is one of very few field studies showing a 
significant effect of antibiotic treatment on clinical coli-
form mastitis. The special characteristics of this study 
were the inclusion of only mild and moderate cases of 
mastitis and the extended duration of intramammary 
therapy. These characteristics may have contributed to 
the improved cure rate. However, the study was also 
characterized by a nonblinded design. Dairy farmers 
were aware that cows were either treated or not treated 
and farmer intervention was specifically allowed in the 
trial design. Thus, some farmer bias toward early inter-
vention in control cows may have occurred. Cows that 
left the study due to intervention by the dairy farmer 
were scored as noncures, resulting in a potentially bi-
ased efficacy of treatment. We would argue, however, 
that this bias is minor because the current treatment 
protocol for clinical mastitis due to coliform infections 
in many dairy farms (including the farms in our study) 
is no intramammary antibiotic treatment at all. Hence, 
the control group was the treatment of choice for the 
farms at the start of the study.
This study showed a significant beneficial effect of 
ceftiofur intramammary treatment on bovine coli-
form mastitis. Although little antimicrobial resistance 
against this third-generation cephalosporin is currently 
present in isolates from bovine mastitis cases, it would 
be prudent to continue to monitor for development of 
resistance in these isolates and commensal species from 
on-farm sources. In human hospital settings, increased 
use of extended-spectrum β-lactamases has reduced the 
Figure 4. Survival curves for time to exit from study (left) and time to culling (right). A comparison of ceftiofur-treated animals with 
controls is shown (top) and animals with bacteriological cure versus noncure (bottom). *Indicates significant difference in curves based on Cox 
regression analysis, P < 0.05. Color version available in the online PDF.
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efficacy of this class of antibiotics (Pfeifer et al., 2010), 
and this resistance has recently been reported in bovine 
mastitis pathogens (Locatelli et al., 2009). An increased 
resistance to third-generation cephalosporin would be 
of potential concern for both veterinary and human ap-
plications.
Spontaneous cure rates of E. coli infections are gener-
ally high. For example, Leininger and coworkers (2003) 
observed that almost all mild and moderate CM cases 
due to E. coli cured within a short time frame, regard-
less of whether antimicrobial treatment or frequent 
milk-out was used. In that study, 85% bacteriological 
cure was observed within 7 d of CM. In the current 
study, however, 47% of infections in untreated control 
quarters did not meet the definition for bacteriological 
cure within the 2-wk follow-up period. The reason for 
this low percentage of spontaneous cure is likely 2-fold. 
First, cows did not have complete follow-up data, which 
we defined as a failure (3 out of the 10 noncures in the 
control group) and second, cows were truly not cured 
and a persistent E. coli infection was present (7 out of 
the 10 noncures in the control group). Persistent E. 
coli mastitis is increasingly recognized as a clinically 
relevant problem with a distinct pathogenesis (Dogan 
et al., 2006; White et al., 2010; Suojala et al., 2011).
Quarters infected with Klebsiella spp. showed a 
relatively high probability of bacteriological cure in 
the treatment group (57%). A similar proportion of 
50% cure was observed after intramuscular ceftiofur 
treatment of 8 animals with severe CM (Erskine et 
al., 2002a), but clearly the number of quarters in that 
study was small. Quarters infected with Klebsiella are 
often considered to have a very low chance of cure. 
In a study by Roberson and colleagues (2004), 37% 
of 19 Klebsiella-infected quarters from cows with mild 
to moderate CM cured within a week, and 47% cured 
within 36 d. In the Erskine et al. (2002a) study of se-
vere CM, only 1 of 4 control cows cured. In our study, 
control quarters infected with Klebsiella spp. had a 
very low probability of spontaneous cure (19%), and 
the improvement in bacteriological cure after 5 d of an-
timicrobial treatment with intramammary ceftiofur was 
statistically significant compared with the nontreated 
control group.
Our data from 5 dairy herds in New York State sug-
gest that distinct bacteriological cure profiles exist for 
the different coliform bacterial species. This different 
cure profile across bacterial species makes it important 
to determine, at least at the herd level, which type of 
coliform is the predominant cause of clinical mastitis in 
the herd. In herds where E. cloacae is dominant, treat-
ment is unlikely to result in any improvements, whereas 
in herds with a dominance of E. coli and Klebsiella spp., 
treatment with ceftiofur hydrochloride for 5 d appears 
to be efficacious.
Coliform mastitis is associated with significant losses 
in milk production that may persist for weeks, par-
ticularly in the case of Klebsiella infections, which were 
reported to cause average losses of 7.6 kg/d shortly af-
ter infection and 5 kg/d in subsequent months (Gröhn 
et al., 2004). In our data, when compared with milk 
production before mastitis, cows lost approximately 10 
kg of milk per day with no bacteriological cure and 
4 kg of milk per day when there was a bacteriologi-
cal cure (Figure 3, second test-day after treatment). 
When quarters were cured of the microorganism that 
was cultured at the time of diagnosis of CM, cows 
responded with a significantly higher milk production 
after completion of treatment. An approximately 6-kg 
increase in daily milk production is an important ben-
efit for the producer investing in antimicrobial therapy, 
additional labor, and the treatment-associated milk 
discards. Clearly, not every treatment resulted in cure 
and not every untreated cow failed to cure; however, 
the probability of cure approximately doubled after 
treatment. Although LS was numerically lower in cured 
cows, no significant difference was observed posttreat-
ment between cured and noncured quarters or between 
treated and control quarters. This was likely due to the 
large variability within groups and the relatively small 
number of cows that contributed to the analyses (n = 
36 out of 104 cows).
Herd survival was significantly higher in bacteriologi-
cally cured animals versus noncured animals. Because a 
cow that was culled before both treatment samples were 
taken was defined as a noncure, it is not surprising to see 
a relationship between the rate of culling and noncure.
Ultimately, the value of treatment needs to be de-
cided based on economic arguments. Precise data, pref-
erably from field trials, are essential in the development 
of valid economic models. The data in this study will be 
helpful in future developments of economic models on 
treatment decisions for gram-negative mild and mod-
erate clinical mastitis. The use of a third-generation 
cephalosporin for bovine mastitis is currently under 
debate. It may be argued that intramammary use of 
this antimicrobial is preferable over systemic use with 
regard to emergence of antimicrobial resistance in mi-
crobiota of the gastrointestinal tract, respiratory mu-
cosa, or skin. A quantification of the risk or emergence 
of resistance after parenteral versus intramammary 
use of ceftiofur hydrochloride would be of considerable 
value in the discussion on rational treatment options 
for bovine mastitis.
In this study, we used genotypic strain typing as the 
gold standard for bacteriological cure. The use of geno-
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typing of bacteria further refines the definition of cure, 
as previously shown for Staphylococcus aureus mastitis 
(Luby and Middleton, 2005). This definition takes 
advantage of current diagnostic technologies (Zadoks 
and Schukken, 2006), but assumes that quarters are 
infected with a single or at least a single dominant 
bacterial strain. Several studies of gram-positive and 
gram-negative mastitis show that this is generally the 
case (Oliver et al., 1998; Phuektes et al., 2001; Young et 
al., 2001; Munoz et al., 2007), although exceptions have 
been described for Klebsiella spp. (Paulin-Curlee et al., 
2007). In the latter study, assessment of reproducibility 
of typing results was not described, whereas we dem-
onstrated that our method had good reproducibility. 
We observed dominant strain types for all 3 bacterial 
species in at least some of the farms. The results chal-
lenge the paradigm that gram-negative infections are 
strictly environmental and suggest that at least some 
of gram-negative infections may be due to cow-to-cow 
transmission or point-source exposure to a common 
strain (Zadoks and Schukken, 2006; Munoz et al., 
2007). To reduce the possibility that lack of discrimina-
tory power explained the presence of the same strain in 
multiple animals, a selection of strains was tested by 
an alternative RAPD protocol that has been used in 
several peer-reviewed studies of E. coli and Klebsiella 
spp. (Lam et al., 1996; Bradley and Green, 2000; Mu-
noz and Zadoks, 2007). As before (Munoz and Zadoks, 
2007), the alternative RAPD protocol did not increase 
the number of strains detected.
CONCLUSIONS
Based on a randomized, controlled clinical trial in 5 
dairy herds with evaluation of production and clinical 
data and bacteriological culture results, treatment of 
nonsevere clinical gram-negative mastitis with ceftiofur 
hydrochloride resulted in significant bacteriological im-
provement compared with nontreated control animals, 
particularly in animals infected with E. coli or Klebsiella 
spp. Treated animals clinically improved significantly 
more compared with control cows. No significant differ-
ences were observed in milk production or linear score 
either before or after clinical mastitis between treated 
and control animals. Treated animals left the study less 
frequently compared with control animals.
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